Germany - Pharmaceuticals
For more information and to make a bid you will need to go to the third party website.
Details
Provided by
- Opportunity closing date
- 10 November 2025
- Opportunity publication date
- 15 November 2023
- Category
- 33600000
- Value of contract
- to be confirmed
- Your guide to exporting
Description
§Section 130a (8) SGB V enables health insurance funds (KK) and pharmaceutical companies to conclude framework discount agreements on the medicines to be dispensed at the expense of the statutory health insurance funds. GWQ acts as a company for efficiency and quality at SHI funds in accordance with Section 130a (8) sentence 5 SGB V for its shareholder and customer SHI funds. With regard to the relevant statutory provisions on the award of public contracts, GWQ ServicePlus AG carries out a regular process of formal award procedures for active pharmaceutical ingredients in accordance with the regulations of Part 4 of the GWB. Until the entry into force of new drug discount agreements, GWQ would like to conclude drug discount agreements with all interested pharmaceutical companies within the framework of the open house procedure for preparations with the above-mentioned active ingredient. The earliest contract start date is 01.01.2024.
GWQ ServicePlus AG also intends to conclude non-exclusive discount agreements in accordance with Section 130a (8) SGB V with a contract start date of January 1, 2024. All interested companies can join this agreement under the same conditions at any time during the term of the agreement (approval model). GWQ assumes that this procedure does not fall within the scope of application of antitrust law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. The contract documents, the participating health insurance funds and their turnover as well as the deadlines for reporting the contract can be viewed and downloaded from the GWQ ServicePlus AG contract award portal at http://vergabeportal.gwq-serviceplus.de. Until the start of exclusive contracts, this transitional agreement is open to all market participants to join. Upon receipt of the signed contracts / declaration and evidence by 10.12.2023, a first notification can be realized as of 01.01.2024.The following documents must be submitted:- signed contract in duplicate,- proof of marketing authorization under pharmaceutical law by means of an extract from the public part of the AMIce database,- signed self-declaration (Annex 3),- list of PZNs covered by the contract (Annex 2),- declaration on Council Regulation (EU) 2022/576 of 08. April 2022 amending Regulation (EU) No 833/2014 concerning restrictive measures in view of Russia's actions destabilizing the situation in Ukraine (Annex 5)
- Opportunity closing date
- 10 November 2025
- Value of contract
- to be confirmed
About the buyer
- Address
- GWQ ServicePlus AG GWQ ServicePlus AG, Ria-Thiele-Str. 2a, 40549 Düsseldorf, handelnd für die unter VI 2.) näher genannten Gesetzlichen Krankenkassen Düsseldorf 40549 Germany
- Contact
- bieteranfrage@gwq-serviceplus.de
Bid for tender
If your company meets the requirements of the tender, go to the website where the tender is hosted and submit your bid.
This website contains links to other websites that we do not control or maintain. We are not responsible for the content of these sites. We provide these links for your convenience only, and do not necessarily endorse their content.
Before entering into a contract you need to apply for any necessary export licences, which can include applications to trade in certain goods. You should also make your own enquiries and be satisfied by the accuracy of any information supplied to you.
This opportunity has been translated from its original language. You should check if you need to apply in the original language.